Abstract
The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Current Pharmaceutical Design
Title:The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Volume: 27 Issue: 23
Author(s): Nikolaos Sofikitis*, Aris Kaltsas, Fotios Dimitriadis, Jens Rassweiler, Nikolaos Grivas, Athanasios Zachariou, Apostolos Kaponis, Panagiota Tsounapi, Napoleon Paterakis, Andreas Karagiannis, Sotirios Skouros, Ioannis Giannakis, Ioannis Champilomatis, Minas Paschopoulos, Diamantis Daphnis, Ioannis Giakoumakis, Melinda R.Gabales, Jo Ben M. Chua, Pedro L. Lantin III, Charalampos Mamoulakis and Atsushi Takenaka
Affiliation:
- Department of Urology, Ioannina University School of Medicine, Ioannina,Greece
Keywords: Spermatozoa, testis, epididymis, phosphodiesterase, prostate, seminal vesicles, PDE5 inhibitors.
Abstract: The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
Export Options
About this article
Cite this article as:
Sofikitis Nikolaos *, Kaltsas Aris , Dimitriadis Fotios , Rassweiler Jens , Grivas Nikolaos , Zachariou Athanasios , Kaponis Apostolos , Tsounapi Panagiota , Paterakis Napoleon , Karagiannis Andreas , Skouros Sotirios , Giannakis Ioannis , Champilomatis Ioannis , Paschopoulos Minas , Daphnis Diamantis , Giakoumakis Ioannis , R.Gabales Melinda , M. Chua Ben Jo , Lantin III L. Pedro, Mamoulakis Charalampos and Takenaka Atsushi , The Effect of PDE5 Inhibitors on the Male Reproductive Tract, Current Pharmaceutical Design 2021; 27 (23) . https://dx.doi.org/10.2174/1381612826666200226121510
DOI https://dx.doi.org/10.2174/1381612826666200226121510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs Involved in Oxidative Stress Processes Regulating Physiological
and Pathological Responses
MicroRNA Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology Cardiovascular and Fluid Volume Control in Humans in Space
Current Pharmaceutical Biotechnology Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review
Current Pharmaceutical Design The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry Pharmacologic Approach to Heart Failure in Children
Current Cardiology Reviews Protein Kinase C Isoforms - Implications to Thrombosis
Current Signal Transduction Therapy Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Inflammatory Biomarkers Predicting Events in Atherosclerosis
Current Medicinal Chemistry Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas
Current Cancer Drug Targets P-Glycoprotein Contributes to Cell Membrane Depolarization of Hippocampus and Neocortex in a Model of Repetitive Seizures Induced by Pentylenetetrazole in Rats
Current Pharmaceutical Design Antiviral Therapy Targeting Viral Polymerase
Current Pharmaceutical Design Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets